Interestingly, treating asymptomatic multiple myeloma (AMM) patients with atezolizumab, the humanized IgG1 monoclonal antibody targeting PD-L1 (12), induced an inflammatory signature in CD14+ monocytes (12), proposing that the PD-L1 axis may shape the myeloid-mediated inflammatory responses. This evidence concerns the gene CD274 and plasma cell myeloma.